What changed
BioMarin beat the Street with Q3 FY26 adjusted EPS of $0.23 versus a $(0.11) consensus, a +304.8% beat. Revenue came in at $1,025M, up 32.1% YoY, crossing $1 billion for the first time. FY2026 guidance: adjusted EPS $2.80–$3.10 and revenue $3.8B–$3.9B. Top-line growth was driven by the Amicus acquisition adding GALAFOLD ($152M) and POMBILITI + OPFOLDA ($49M), plus 18% VIMIZIM growth on international order timing, partially offset by lower NAGLAZYME revenue.
Why it matters
BioMarin beat the Street with Q3 FY26 adjusted EPS of $0.23 versus a $(0.11) consensus, a +304.8% beat. Revenue came in at $1,025M, up 32.1% YoY, crossing $1 billion for the first time. FY2026 guidanc